Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innospec (IOSP) Cash & Equivalents (2016 - 2025)

Innospec (IOSP) has disclosed Cash & Equivalents for 16 consecutive years, with $292.5 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 1.14% to $292.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $292.5 million through Dec 2025, up 1.14% year-over-year, with the annual reading at $292.5 million for FY2025, 1.14% up from the prior year.
  • Cash & Equivalents hit $292.5 million in Q4 2025 for Innospec, up from $270.8 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $303.8 million in Q3 2024 to a low of $71.4 million in Q2 2022.
  • Historically, Cash & Equivalents has averaged $191.2 million across 5 years, with a median of $184.8 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: fell 24.36% in 2022 and later soared 132.35% in 2023.
  • Year by year, Cash & Equivalents stood at $141.8 million in 2021, then rose by 3.74% to $147.1 million in 2022, then surged by 38.48% to $203.7 million in 2023, then skyrocketed by 41.97% to $289.2 million in 2024, then grew by 1.14% to $292.5 million in 2025.
  • Business Quant data shows Cash & Equivalents for IOSP at $292.5 million in Q4 2025, $270.8 million in Q3 2025, and $266.6 million in Q2 2025.